
<SEC-DOCUMENT>0001095435-16-000057.txt : 20160805
<SEC-HEADER>0001095435-16-000057.hdr.sgml : 20160805
<ACCEPTANCE-DATETIME>20160805102623
ACCESSION NUMBER:
CONFORMED SUBMISSION TYPE:
PUBLIC DOCUMENT COUNT:
CONFORMED PERIOD OF REPORT:
FILED AS OF DATE:
DATE AS OF CHANGE:
6-K
1
20160805
0001095435-16-000057
20160805
20160805
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME:
CENTRAL INDEX KEY:
STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS
PORTAGE BIOTECH INC.
0001095435
[1311]
IRS NUMBER:
STATE OF INCORPORATION:
FISCAL YEAR END:
000000000
A6
0331
FILING VALUES:
FORM TYPE:
SEC ACT:
SEC FILE NUMBER: 000-30314
FILM NUMBER:
6-K
1934 Act
161809464
BUSINESS ADDRESS:
STREET 1:
STREET 2:
CITY:
STATE:
ZIP:
BUSINESS PHONE:
47 AVENUE ROAD
SUITE 200
TORONTO
A6
M5R 2G3
416-929-1806
MAIL ADDRESS:
STREET 1:
STREET 2:
CITY:
STATE:
ZIP:
47 AVENUE ROAD
SUITE 200
TORONTO
A6
M5R 2G3
FORMER COMPANY:
FORMER CONFORMED NAME: BONTAN CORP INC
DATE OF NAME CHANGE:
20030421
FORMER COMPANY:
FORMER CONFORMED NAME: DEALCHECK COM INC
DATE OF NAME CHANGE:
19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>pr8516.htm
<DESCRIPTION>PORTAGE APPOINTS A NEW DIRECTOR
<TEXT>
<html>
<head>
<title>&#160;</title>
<!--Licensed to: Portage Biotech iNC.
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">UNITED STATES SECURITIES AND EXCHANGE 
COMMISSION Washington, D.C. 20549</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Form 6-K</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO 
RULE 13a-16 OR 15d-16</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">UNDER THE SECURITIES EXCHANGE ACT OF 
1934</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">For the month of August 2016</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">Commission File Number 0-30314</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">&#160;</div>
<div style="FONT-SIZE: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">PORTAGE BIOTECH INC.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">(Translation of registrant's name into English)</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">47 Avenue Rd., Suite 200, Toronto, Ontario, 
Canada M5R 2G3</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">(Address of principal executive office)</div>
<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">Indicate by check mark whether the 
registrant files or will file annual reports under cover Form 20-F or Form 40-
F.&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">Form 20-F ___X___ Form 40-F 
_______</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation&#160;S-T Rule 
101(b)(1):&#160;&#160;______</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation&#160;S-T Rule 
101(b)(7):&#160;______&#160;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">Indicate by check mark whether the 
registrant by furnishing the information contained in this Form is also thereby 
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under 
the Securities Exchange Act of 1934.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">Yes _______ No___X____</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">If "Yes" is marked, indicate below the 
file number assigned to the registrant in connection with Rule 12g3-2(b):</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; BACKGROUND-COLOR: #ffffff">82- ______________.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR:
both">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">SIGNATURES</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;Pursuant to the requirements of the Securities Exchange Act 
of 1934, the registrant has duly caused this report to be signed on its behalf 
by the undersigned, thereunto duly authorized.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Dated: August 5, 2016</div>
<div style="TEXT-ALIGN: left"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">PORTAGE BIOTECH INC.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">By: /s/ Kam Shah</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Kam Shah</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Chief Financial Officer</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR:
both">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div><br>
</div>
<div>&#160;</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">NEWS RELEASE</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>PORTAGE 
ANNOUNCES APPOINTMENT OF NEW DIRECTOR</u></div>
<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; BACKGROUND-COLOR: 
#ffffff">Toronto, Ontario, August 5, 2016 &#8211; </font><font style="FONT-SIZE:
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: 
#ffffff">Portage Biotech Inc. ("Portage" or "the Company")</font><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; BACKGROUND-COLOR: #ffffff"> (OTC: PTGEF, Canadian Securities 
Exchange: PBT.U)</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; BACKGROUND-COLOR: #ffffff">, announces the appointment of 
Dr. Ian Walters as an independent Director of the Company and a member of our 
Audit and Compensation committee effective August 1, 2016. Portage now has six 
Directors.</font></div>
<div><br>
</div>
</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">Ian Walters, M.D., M.B.A. is an 
experienced life science entrepreneur who has helped found and launched several 
life science companies.&#160; He is currently the founder and CEO of SalvaRx 
(LON: SALV) and iOx Therapeutics, a SalvaRx portfolio company.&#160; He is also 
the Chief Medical Officer for Intensity Therapeutics.&#160;&#160;Dr 
Walters&#160;has led drug development teams in several therapeutic 
areas&#160;and contributed to bringing 4 blockbuster products to market, 
including Opdivo&#174;, Yervoy&#174;, and Velcade&#174;. While Dr. Walters 
worked at BMS,&#160;he managed physicians overseeing the international 
development of more than 8 oncology compounds as well as biomarker and companion
diagnostic work.&#160; He also was a core member of BMS's Strategic Transactions
Group evaluating and executing licensing agreements, mergers and acquisitions, 
and clinical collaborations. &#160; &#160;Before entering the private sector, 
Dr. Walters was a lead investigator at the Rockefeller University and initiated 
cutting edge immunology research to understand the mechanism of action of 
several compounds. Dr. Walters received his MD from the Albert Einstein College 
of Medicine and an MBA from the Wharton School of the University of 
Pennsylvania.</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">Dr Walters commented, "I am excited by 
the progress that Portage has made so far, and I am thrilled to guide the team 
as they begin to deliver on their current programs and evaluate new 
opportunities. "</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Dr. Gregory 
Bailey, the Chairman commented, "Dr. Walters is great addition to the Portage 
board with his comprehensive background in medicine, business and drug 
development. He also has an extensive network in the biotech sector. It is my 
pleasure to welcome him to our team and look forward to his input</font><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
BACKGROUND-COLOR: #ffffff"> as an independent director </font><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: 
#ffffff">going forward."&#160;</font></div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; 
BACKGROUND-COLOR: #ffffff">About Portage</font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: 
#ffffff">:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; BACKGROUND-COLOR: #ffffff">Portage is engaged in the discovery and 
development of pharmaceutical and biotech products through clinical "proof of 
concept" with a focus on areas of unmet clinical need. Following proof of 
concept, Portage will seek to sell or license these products to large 
pharmaceutical or biotechnology companies for further development and 
commercialization.</font></div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Portage is seeking discovery and co-
development partners with expertise in areas such as cancer, infectious disease,
neurology and psychiatry in order to develop and commercialize its therapies. 
Portage has an interest in novel targeted therapies, stem cell therapies, and 
new indications for older marketed products that have been found to have novel 
patentable characteristics that bring new value to patients.</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Portage looks to work with a wide 
range of partners in all phases of development. Collaboration with Portage may 
include direct funding of other companies or investing human capital from our 
extensive pool of talented scientists and physicians. Specifically, Portage 
invests sweat equity as well as, or instead of, capital. Portage's network of 
associated drug developers, financiers, scientists and physicians can provide 
substantial value for our partners by mitigating risks, designing clinical 
trials, providing regulatory expertise, and maximizing the rewards of clinical 
development.</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Portage has two operating 
subsidiaries &#8211; Portage Pharmaceuticals Limited ("PPL"), which is wholly 
owned by Portage, and Biohaven Pharmaceutical Holding Company Limited 
("Biohaven") in which Portage holds approximately 52% equity.&#160; In addition,
Portage holds an unconsolidated investment in Sentien Biotechnologies Inc. 
( Sentien).</div>
<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR:
both">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">refer to our
latest updates on all our operating group companies on our website at 
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">http://www.portagebiotech.com/images/pdf/Portage_Biotech_July_14th_Confer
ence_Call_Transcript.pdf</font></div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif">Portage has recently filed its annual 
report and audited financial statements for the year ended March 31, 2016. These
documents can be found at </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, 
serif">https://www.sec.gov/Archives/edgar/data/1095435/000139390516000989/000139
3905-16-000989-index.htm</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times
New Roman', Times, serif">&#160; on EDGAR and at </font><font style="FONT-SIZE:
10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">http://www.sedar.com/DisplayCompanyDocuments.do?
lang=EN&amp;issuerNo=00008656</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif"> on SEDAR web sites.</font></div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">For further 
information, contact Kam Shah, Chief Financial Officer, at&#160;</font><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
BACKGROUND-COLOR: #ffffff">(416) 929-1806</font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">.or 
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; BACKGROUND-COLOR: #ffffff">ks@portagebiotech.com</font><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: 
#ffffff"> .or our web site </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; BACKGROUND-COLOR: 
#ffffff">www.portagebiotech.com</font></div>
<div style="MARGIN-BOTTOM: 10pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt;
FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: 
#ffffff"><u>Forward-Looking Statements</u></font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font></font><br>
</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">This news 
release includes forward-looking statements within the meaning of the U.S. 
federal and Canadian securities laws. &#160;Any such statements reflect 
Portage's current views and assumptions about future events and financial 
performance. &#160;Portage cannot assure that future events or performance will 
occur. Important risks and factors that could cause actual results or events to 
differ materially from those indicated in our forward-looking statements.</div>
<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
<div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">Portage 
assumes no obligation and expressly disclaims any duty to update the information
in this News Release.</div>
<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>